Anthony P. Bihl III Named New Bioventus Chief Executive Officer
DURHAM, N.C. – November 21, 2013 – Bioventus, a leader in active orthopaedic healing, today announced that Anthony P. Bihl III will join the company on Dec. 2, 2013 as its new Chief Executive Officer. Bihl, an experienced healthcare industry executive known for building high-performing teams, driving operational improvements and achieving exceptional financial results, will also serve on the company’s Board of Managers.
“Tony’s strategic aptitude, coupled with his proven track record of producing extraordinary results, made him the perfect choice to lead Bioventus,” said Marty Sutter, Founding Partner and Managing Director of Essex Woodlands, a specialist healthcare growth equity firm and the lead investor in Bioventus. “We’re pleased to have him join the company and are confident he will help propel Bioventus to even greater success.”
“I’m excited for the opportunity to lead Bioventus, a company on the verge of establishing itself as a global biologics leader,” Bihl said. “Although the current healthcare environment is challenging for many companies, Bioventus is in the unique position of leveraging what it has today – proven, market-leading offerings – while aggressively planning for the future, through its development projects and product acquisition strategy. I look forward to working with the Bioventus leadership team to capitalize on these opportunities.”
Bihl, 57, previously served as CEO and President of American Medical Systems (AMS), a publicly-traded diversified supplier of medical devices and pelvic procedures. During his four years with the company, he led its restructuring following a series of acquisitions, strengthened its management team, established a performance-based culture with clear accountability, and achieved revenue growth and grew operating profit. In 2011, Bihl led the company to its successful sale to Endo Pharmaceuticals.
Prior to AMS, Bihl was CEO of Siemens Medical Solutions Diagnostics, a $2.5 billion division of Siemens AG focused on the in vitro diagnostics (IVD) market. There, he led the formation of the division by successfully integrating two business units involving more than 8,000 employees and operations in 100 countries – all while achieving sales growth faster than market growth and exceeding profit targets.
Bihl also served as President of the $1.8 billion diagnostics division of Bayer Healthcare LLC, and as Executive Vice President for Bayer Healthcare LLC. He consistently grew sales for the division and managed the strategic discussions and due diligence that resulted in the division’s acquisition by Siemens for $5.4 billion.
Before joining Bayer, Bihl held management positions at Sterling Diagnostic Imaging and E.I. DuPont.
Bihl currently holds Board seats and provides strategic leadership for Greatbatch Inc., a medical device and components developer and manufacturer; and Spectral Diagnostics Inc., a diagnostics company with the only FDA cleared test for risk of developing severe sepsis.
He holds a Bachelor of Science with distinction degree from Pennsylvania State University.
Bioventus is a biologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company’s innovative products include market-leading devices, therapies and diagnostics that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine, and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com or follow the company on Facebook (www.facebook.com/bioventus) or Twitter (@BioventusGlobal or www.twitter.com/BioventusGlobal).